Direct inquiries for additional copies of

Tobacco, Alcohol, & Other Drug Abuse Trends in Washington State,

to:

Washington State Alcohol & Drug Clearinghouse
1-800-662-9111

This report is also available on the
Division of Alcohol and Substance Abuse website:
www1.dshs.wa.gov/dasa/

Tobacco, Alcohol, and Other Drug Abuse Trends in Washington State

2004 Report



David H. Albert

December 2004

Kenneth D. Stark, Director
Division of Alcohol and Substance Abuse
Washington State Department of Social and Health Services
Olympia, WA 98504-5330

Acknowledgments

Production of the *2004 Trends Report* required the assistance and collaboration of many individuals. Werner Ide of WIDE Designs continues to provide excellent services in designing this *Report*. For their varied and wide-ranging contributions to this *Report*, we wish to thank the following individuals:

Washington State Department of Social and Health Services (DSHS)

Division of Alcohol and Substance Abuse

Renee Anderson
Glenn Baldwin
Linda Becker
Steve Bogan
Kevin Campbell
Vince Collins
Pam Darby
Fred Garcia
Jennifer Gau
Annabeth Goldrick
Ella Hanks
Toni Krupski
Michael Langer
Ruth Leonard
Neva Leons
Earl Long
Sandra Mena
Rose Mary Micheli
Terrie Orphey
Tom Pennella
Harvey Perez
Felix Rodriguez
Deb Schnellman
Aaron Starks
Steve Smothers
Ed Vukich
Scott Waller
Fritz Wrede

Office of Research and Data Analysis

Sharon Estee
Michael Gilson
Elizabeth Kohlenberg
David Mancuso
Daniel Nordlund

Chuck Anderson
Caleb Banta-Green
Molly Carney
Michael Hanrahan
Steve Hunter
Jeanette Neibert
Patricia Noble
Phil Salzberg
Mike Towey
Cynthia Walker

Table Of Contents

Adult Substance Use

AREAS OF SUBSTANCE ABUSE IMPACT

Birth Impacts

Accident Risks

Health Consequences

Infectious Diseases

Crime

Treatment Completion

THE FUTURE: POLICY ISSUES CONFRONTING WASHINGTON STATE

DATA SOURCES

GARY LOCKE
Governor

STATE OF WASHINGTON
OFFICE OF THE GOVERNOR
P.O. Box 40002 • Olympia, Washington 98504-0002 • (360) 753-6780 • www.governor.wa.gov

Message from the Governor

November 2004

I am pleased to share with you the 2004 edition of Tobacco, Alcohol, & Other Drug Abuse Trends in Washington State. This reports makes clear the great and continuing stake we all share in finding ways to combat the misuse of alcohol, tobacco, and drugs, which exact such a heavy tool upon Washington's communities.

This publication provides a wealth of information regarding the prevalence of substance abuse among youth and adults, as well as its effects upon our health and well-being. Addiction to alcohol, tobacco, and drugs is both a public health and public safety issue. It results in increased violence, crime, delinquency, birth defects, and illnesses. It inhibits economic vitality, and makes our efforts to improve education much more difficult.

Fortunately, as this Trends report makes clear, prevention strategies and treatment programs are working. The coordinated efforts of prevention and treatment professionals, law enforcement, and schools are helping to build a safer, healthier Washington for all of us.

As we prepare to meet our future challenges, I am acutely aware of the importance of having reliable and comprehensive information to assist decision-making at both the state and local level. This report serves as an important and valuable tool for distributing facts to guide us in our continuing efforts to improve the health and safety of the people of Washington.

Sincerely,

Gary Locke
Governor

Message from the Acting Director

Another year rolls around, and already we at the Division of Alcohol and Substance Abuse (DASA) are planning for a new Biennium. There will be changes of course. 2005 will see the installation of a new Governor. A new Legislature will wrestle with problems of a tight budget, ways to secure the safety net for Washington's most vulnerable residents, and the need to expand economic opportunity.

We at DASA believe we are part of the solution to these problems. As detailed in this, the 12th *Tobacco, Alcohol, and Other Drug Abuse Trends in Washington State* report, the evidence is clear. Providing quality substance abuse prevention, intervention, and treatment services saves money and saves lives. They result in healthier and more productive individuals and families, safer communities, and children and youth with brighter futures.

DASA's commitment to research is part of our longer-term strategy to educate policymakers and the public about the effectiveness of substance abuse prevention and treatment services. This *2004 Report* highlights new research that makes this ever more apparent. Treatment for methamphetamine addiction results in lower health costs and reduced arrests and convictions. Treatment of substance-abusing pregnant and parenting women (through the Safe Babies, Safe Moms program) results in fewer lower birthweight infants, fewer accepted Child Protective Services referrals, less criminal justice involvement. Treatment for youth through the Chemical Dependency Disposition Alternative (CDDA) results in fewer convictions and criminal justice detentions; higher rates of school enrollment; more employment; better family and social relationships. Opiate substitution treatment reduces health costs, arrests, and convictions.

Evidence of the effectiveness of both prevention and treatment has expanded our capacity to enter into more than a dozen collaborative relationships with our partners in both the public and private sector, and at the local, state, federal level. Collaborations include the State Mentoring Partnership, the Healthy Youth Survey, integrated residential services for men with co-occurring disorders, the stationing of chemical dependency professionals in Community Services Offices statewide, coordinated services offered through the Hepatitis AIDS Substance Abuse Program, and the promotion of Drug-Free Workplaces.

Two recent collaborations illustrate further the potential impact of working closely with our partners. Through a federal grant, the Washington State Screening, Brief Intervention, Referral, and Treatment (WASBIRT) program provides for substance abuse screening and access to needed services through six hospital emergency departments across the state. By intervening during a crisis, and a time during which individuals may be most open to prevention and treatment messages, it is hoped that substance abuse problems can be addressed before they cycle out of control. Through funds allocated by the Legislature to the Criminal Justice Treatment Account, drug offenders at the county level may now be able to access treatment in lieu of incarceration, thus preventing costly imprisonments and returning individuals in recovery to their communities.

More remains to be done. With our community partners, DASA remains committed to a healthier Washington. We look forward to continuing to join with others to ensure all our citizens are well-equipped to lead happier, more productive lives in communities free of the devastation wrong by alcohol, tobacco, and drug abuse.

Doug Allen

The Division of Alcohol and Substance Abuse: Mission and Strategic Goals

In 2004, the Division of Alcohol and Substance Abuse (DASA), with the assistance of the Citizens Advisory Council on Alcoholism and Drug Addiction and others, adopted a new Strategic Plan for 2006-2011. In doing so, DASA revisited its Mission Statement to ensure that it continues to reflect the needs of Washington residents and the philosophy behind the Division's operations.

Mission

The Mission of the Department of Social and Health Services is to improve the quality of life for individuals and families in need. We will help people to achieve safe, self-sufficient, healthy and secure lives. The Division of Alcohol and Substance Abuse promotes strategies that support healthy lifestyles by preventing the misuse of alcohol, tobacco, and other drugs, and support recovery from the disease of chemical dependency.

To succeed in its Mission, the Division of Alcohol and Substance Abuse is dedicated to building collaborative partnerships with communities, tribes, counties, service providers, schools, colleges and universities, the criminal justice system, and other agencies within the private sector and within local, state and federal governments. The Division is committed to ensuring services are provided to individuals and communities in ways that are culturally relevant, and honor the diversity of Washington State.

To carry forth our Mission, the Division of Alcohol and Substance Abuse will:

- Develop policy options, and plan for the development and delivery of an effective continuum of chemical dependency prevention and treatment services;
- Provide and ensure quality services that support individuals and families in their efforts to raise children who are free of alcohol, tobacco, and other drugs;
- Educate communities about the importance of maintaining healthy lifestyles, and provide opportunities, tools and resources to enable communities to define and meet their local substance abuse prevention needs;
- Implement a continuum of intervention and treatment services to meet local, regional, tribal and statewide needs, and which specifically address the needs of low-income adults, youth, women, children, and families;
- Support continued recovery and a return to competitive employment by helping individuals surmount barriers to self-sufficiency;

- Develop standards, and assist providers in attaining, maintaining, and improving the quality of care for individuals and families in need of prevention and treatment services;
- Provide training and professional development opportunities for the chemical dependency field;
- Oversee and coordinate research that identifies need for publicly funded services, and assesses prevention and treatment;
- Provide management information services and support to internal and external customers;
- Manage available resources in a manner consistent with sound business practices; and
- Advocate for the enhanced availability of, and resources for, prevention and treatment services as a primary avenue for protecting and promoting the public health and safety of all Washington residents.

Strategic Goals

As part of its Strategic Plan and to serve its broader mission, DASA has set eight strategic goals for 2006-2011:

- Protect vulnerable adults, children, and families;
- Break down barriers to self-sufficiency;
- Assure public safety and help build strong, healthy communities;
- Reduce misuse and improve lives through preventive action;
- Honor diversity and promote equal access and opportunity;
- Promote accountability, customer service, and public stewardship in policy, programs, and practice;
- Improve quality through innovation, technology and research; and
- Build a strong, committed workforce.

Introduction

The Division of Alcohol and Substance Abuse (DASA) first published the *Tobacco, Alcohol, and Other Drug Abuse Trends Report* in 1993 as an effort to document and monitor Washington State's progress towards the ***Healthy People 2000: National Health Promotion and Disease Prevention Objectives***. Published in 1990, ***Healthy People 2000*** provided statistical milestones by which health policy makers and analysts can measure progress in the prevention of morbidity and mortality. A successor – ***Healthy People 2010*** – published by the U.S. Department of Health and Human Services, sets new objectives for the current decade.

Healthy People 2000 noted the significant impact that alcohol, tobacco, and other drugs have on the health of individuals and communities:

> Recognition and acknowledgement of the gravity of alcohol and other drug problems in the United States are changing the social climate. Almost every national opinion poll places alcohol and other drug problems as a priority concern, and the national effort to prevent these problems have mobilized government, schools, communities, businesses, and families...Progress will depend greatly upon increasing levels of education and awareness.[1]

Public education and awareness are integral parts of DASA's goal – to reduce the likelihood of individuals becoming chemically dependent, and to provide an opportunity for chemically dependent persons to achieve and maintain recovery. This *Report* represents an important tool in our ongoing efforts towards this goal.

This is the 12th edition of *Tobacco, Alcohol, and Other Drug Abuse Trends*. We continue to expand and refine the *Report*. This year, we have added a new section "Prevention Works!" to begin to document more fully the use and effectiveness of evidence-based prevention practices among Washington communities. There is new information regarding the effectiveness of treatment for individuals addicted to methamphetamine. Data regarding the extent of substance use, substance use disorders, and need for treatment is updated based on findings from the *2003 Washington State Needs Assessment Household Survey*. Areas where new or changed trends are now being identified are clearly marked. Finally, there are three new essays on policy issues confronting Washington State. They are:

- Brief Interventions in Emergency Department and Health Care Settings;
- Substance Abuse and Child Welfare; and
- Treatment for Nicotine Dependence.

[1] U.S. Public Health Service, Healthy People 2000: National Health Promotion and Disease Prevention Objectives, pp. 164-165. Washington, DC: U.S. Department of Health and Human Services, 1990.

The federal Controlled Substance Act (CSA) of 1970 gave Congress the authority to regulate the interstate commerce of drugs, and established five schedules that classify all substances, which were in some manner regulated under existing federal law. The placement of each drug is based upon the substance's medical use, potential for abuse, safety, and risk of dependence. The Act also provides a mechanism for substances to be controlled, or added to a schedule; decontrolled, or removed from control; and rescheduled or transferred from one schedule to another.

In determining into which schedule a drug or other substance should be placed, or whether a substance should be decontrolled or rescheduled, certain factors are required to be considered as follows:

- The drug's actual or relative potential for abuse;
- Scientific evidence of the drug's pharmacological effects;
- The state of current scientific knowledge regarding the substance;
- Its history and current pattern of abuse;
- The scope, duration, and significance of abuse;
- What, if any, risk there is to the public health;
- The drug's psychic or physiological dependence liability; and
- Whether the substance is an immediate precursor of a substance already controlled.

Schedule I

- The drug or other substance has a high potential for abuse.
- The drug or other substance has no currently accepted medical use in treatment in the United States.
- There is a lack of accepted safety for use of the drug or other substance under medical supervision.
- Some Schedule I substances are heroin, LSD, marijuana, and methaqualone.

Schedule II

- The drug or other substance has a high potential for abuse.
- The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
- Abuse of the drug or other substance may lead to severe psychological or physical dependence.
- Schedule II substances include morphine, PCP, cocaine, methadone, and methamphetamine.

Schedule III

- The drug or other substance has a potential for abuse less than the drugs or other substances in Schedules I and II.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
- Anabolic steroids, codeine, and hydrocodone with aspirin or Tylenol, and some barbiturates are Schedule III substances.

Schedule IV

- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule III.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule III.
- Included in Schedule IV are Darvon, Talwin, Equanil, Valium, Xanax, and Soma.

Schedule V

- The drug or other substance has a low potential for abuse relative to the drugs or other substances in Schedule IV.
- The drug or other substance has a currently accepted medical use in treatment in the United States.
- Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in Schedule IV.
- Over-the-counter cough medicines with codeine are classified in Schedule V.

Controlled Substances Uses and Effects

Drugs	CSA Schedules	Trade or Other Names	Medical Uses
NARCOTICS			
Heroin	I	Diacetylmorphine, Horse, Smack	None in U.S., Analgesic, Antitussive
Morphine	II	Duramorph, MS-Contin, Oramorph SR, Roxanol	Analgesic
Codeine	II, III, V	Empirin w/Codeine, Fiorinal w/Codeine, Robitussin A-C, Tylenol w/Codeine	Analgesic, Antitussive
Hydrocodone	II, III	Lorcet, Hycodan, Tussionex, Vicodin	Analgesic, Antitussive
Hydromorphone	II	Dilaudid	Analgesic
Oxycodone	II	Percocet, Percodan, Roxicet, Roxidodone, Tylox	Analgesic
Methadone and LAAM	I, II	Dolophine, levomethadyl acetate, Orlaam	Analgesic, Treatment of Dependence
Fentanyl and Analogs	I, II	Alfenta, Duragesic, Innovar, Sufenta	Analgesic, Anesthetic
Other Narcotics	II, III, IV, V	Buprenex, Darvon, Demerol, opium, Talwin	Analgesic, Antidiarrheal
DEPRESSANTS			
Chloral Hydrate	IV	Noctec, Somnos, Felsules	Hypnotic
Barbiturates	II, III, IV	Amytal, Florinal, Nembutal, Seconal, Tuinal	Anesthetic, Anticonvulsant, Sedative, Hypnotic, Veterinary Euthanasia Agent
Benzodiazepines	IV	Ativan, Dalmane, Diazepam, Halcion, Librium, Paxipam, Rohypnol[2], Serax, Tranxene, Valium, Versed, Xanax	Antianxiety, Sedative, Anticonvulsant, Hypnotic
Glutethimide	II	Doriden	Sedative, Hypnotic
Gamma Hydroxybutyrate[1]	I	GHB, Georgia Home Boy, Liquid Ecstasy	None in U.S.
Other Depressants	I, II, III, IV	Equanil, Miltown, Noludar, Placidyl, Valmid, Soma	Antianxiety, Sedative, Hypnotic

Source: U.S. Department of Justice, Drug Enforcement Administration

[1] Washington State Board of Pharmacy has GHB and related analogs included in Schedule III.
[2] Some of the following drug names are products that may contain other active agents.

Physical Dependence	Psychological Dependence	Tolerance	Duration (Hours)	Usual Method	Possible Effects	Effects of Overdose	Withdrawal Syndrome
NARCOTICS							
High	High	Yes	3 - 6	Injected, Sniffed, Smoked	• Euphoria • Drowsiness • Respiratory depression • Constricted pupils • Nausea	• Slow & shallow breathing • Clammy skin • Convulsions • Coma • Possible death	• Watery eyes • Runny nose • Yawning • Loss of appetite • Irritability • Tremors • Panic • Cramps • Nausea • Chills & sweating
High	High	Yes	3 - 6	Oral, Smoked, Injected			
Moderate	Moderate	Yes	3 - 6	Oral, Injected			
High	High	Yes	3 - 6	Oral			
High	High	Yes	3 - 6	Oral, Injected			
High	High	Yes	4 - 5	Oral			
High	High	Yes	12 - 72	Oral, Injected			
High	High	Yes	10 - 72	Injected, Trans-dermal Patch			
High-Low	High-Low	Yes	Variable	Oral, Injected			
DEPRESSANTS							
Moderate	Moderate	Yes	5 - 8	Oral	• Slurred speech • Disorientation • Drunken behavior without odor of alcohol	• Shallow respiration • Clammy skin • Dilated pupils • Weak & rapid pulse • Coma • Possible death	• Anxiety • Insomnia • Tremors • Delirium • Convulsions • Possible death
High-Mod.	High-Mod.	Yes	1 - 16	Oral, Injected			
Low	Low	Yes	4 - 8	Oral, Injected			
High	Moderate	Yes	4 - 8	Oral			
Unknown	Unknown	Yes	Dependent on dose	Oral, Snorted			
Moderate	Moderate	Yes	4 - 8	Oral			

Controlled Substances Uses and Effects

Drugs	CSA Schedules	Trade or Other Names	Medical Uses
STIMULANTS			
Cocaine	II	Coke, Flake, Snow, Crack	Local anesthetic
Amphetamine/Methamphetamine	II	Adderall, Desoxyn, Dexedrine	Attention deficit disorder, narcolepsy, weight control
Methylphenidate	II	Ritalin	Attention deficit disorder, narcolepsy
Other Stimulants	II, III, IV	Adipex, Didrex, Ionamin, Melfiat, Meridia, Plegine, Prelu-2, Preludin, Sanorex, Tenuate, Tepanil	Weight control
CANNABIS			
Marijuana	I	Acapulco Gold, Grass, Mary Jane, Pot, Reefer, Sinsemilla, Thai Sticks	None
Tetrahydrocannabinol	I, II	Marinol, THC	Antinauseant
Hashish and Hashish Oil	I	Hash, Hash Oil	None
HALLUCINOGENS			
LSD	I	Acid, Boomers, Microdot, Trips	None
Mescaline & Peyote	I	Buttons, Cactus, Mescal	None
Amphetamine Variants	I	DOM, DOB, Ecstasy, MDA, MDMA, Nexus, STP	None
Phencyclidine & Analogs	I, II	Angel Dust, Hog, Loveboat, PCE, PCP, TCP	None
Ketamine	III	Ketaject, Ketalar	General anesthetic
Other Hallucinogens	I	Bufotenine, DMT, Ibogaine, Psilocybin, Psilocyn	None
ANABOLIC STEROIDS			
Testosterone (Cypionate, Enanthate)	III	Androderm, Delatestryl, Depo-Testosterone	Hypogonadism
Nandrolone (Decanoate, Phenpropionate)	III	Deca-Durabolin, Durabolin, Nortestonsterone	Anemia, Breast cancer
Oxymetholone	III	Anadrol-50	Anemia

Source: U.S. Department of Justice, Drug Enforcement Administration; National Institute on Drug Abuse

Physical Dependence	Psychological Dependence	Tolerance	Duration (Hours)	Usual Method	Possible Effects	Effects of Overdose	Withdrawal Syndrome
STIMULANTS							
Possible	High	Yes	1 - 2	Sniffed, Smoked, Injected	• Increased alertness • Excitation • Euphoria • Increased pulse rate & blood pressure • Insomnia • Loss of appetite	• Agitation • Increased body temperature • Hallucinations • Convulsions • Possible death	• Apathy • Long periods of sleep • Irritability • Depression • Disorientation
Possible	High	Yes	2 - 4	Oral, Injected, Smoked			
Possible	High	Yes	2 - 4	Oral, Injected			
Possible	High	Yes	2 - 4	Oral, Injected			
CANNABIS							
Unknown	Moderate	Yes	2 - 4	Smoked, Oral	• Euphoria • Relaxed inhibitions • Increased appetite • Disorientation	• Fatigue • Paranoia • Possible psychosis	• Occasional reports of insomnia • Hyperactivity • Decreased appetite
Unknown	Moderate	Yes	2 - 4	Smoked, Oral			
Unknown	Moderate	Yes	2 - 4	Smoked, Oral			
HALLUCINOGENS							
None	Unknown	Yes	8 - 12	Oral	• Illusions and hallucinations • Altered perception of time and distance	• Longer • More intense "trip" episodes • Psychosis • Possible death	• Unknown
None	Unknown	Yes	8 - 12	Oral			
Unknown	Unknown	Yes	Variable	Oral, Injected			
Unknown	High	Yes	Days	Oral, Smoked			
Unknown	Unknown	Yes	Variable	Injected, Oral, Smoked			
None	Unknown	Possible	Variable	Smoked, Oral, Injected, Sniffed			
ANABOLIC STEROIDS							
Unknown	Unknown	Unknown	14 - 28 Days	Injected	• Virilization • Acne • Testicular atrophy • Gynecomastia • Agressive behavior • Edema	• Unknown	• Possible depression
Unknown	Unknown	Unknown	14 - 21 Days	Injected			
Unknown	Unknown	Unknown	24	Oral			

Street Prices for Illicit Drugs

DRUG	UNIT	AVERAGE STREET PRICE	RANGE
Heroin	GRAM OUNCE	$81 $986	$20-$180 $350-$4,000
Cocaine	GRAM OUNCE	$67 $732	$20-$100 $400-$1,000
Methamphetamine	GRAM OUNCE	$64 $723	$30-$180 $425-$1,500
Cannabis	GRAM OUNCE	$15 $293	$10-$40 $100-$500

Source: Northwest High Intensity Drug Trafficking Area (NW HIDTA), Threat Assessment – May 2004.

The Northwest High Intensity Drug Trafficking Area (HIDTA) periodically gathers data on both the street prices and availability of common illicit drugs of abuse. Information is compiled from the Drug Enforcement Agency, U.S. Border Patrol, area narcotics taskforces, sheriff's offices, police departments, and the Coast Guard. Both price and availability can vary widely, both by region and by county.

New/Changing Trends for 2004

Preparation of the *Trends Report* annually makes it possible to examine data for new or changing trends. Such trends can mark the success of failure of a recent legislative effort, a new intervention or change in public health practice, or changes in behavior. They may point the way toward increased need for surveillance, research and analysis, or reorientation in the delivery of public services.

For 2004, the following new or changing trends are worthy of note:

- Chronic drinking rates in Washington State are on the rise, and are at their highest point in more than a decade. (page 68)
- The rate of alcohol-related traffic fatalities has significantly declined, and appears to be associated with the lowering of the BAC standard necessary for a DUI determination. (page 77)
- The drug-induced death rate in Washington State is almost double what it was in 1993. (page 84)
- Rates of heroin-related deaths in Seattle-King County are again on the rise. (page 87)
- The number of other opiates identified in drug-caused deaths in King County has quadrupled since 1994. (page 88)
- There is a significant increase in of primary and secondary syphilis cases. (page 101),
- Gonorrhea rates have increased more than 50% since 1998, and are associated with men having sex with men. (page 102)
- The number of reported methamphetamine laboratories/dumpsites continues to fall. (page 109)
- Arrests for drug abuse violations have increased significantly over the past decade. (page 115)
- The costs of imprisoning felony drug offenders continues to rise, and now stands at $89.1 million per year. (page 118)
- Waiting lists for treatment under the Alcohol and Drug Abuse Treatment and Support Act have quadrupled since 1991, and have risen rapidly in the past three years. (page 206)
- Washington has made a major commitment to providing chemical dependency treatment to offenders. (page 240)